Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients.

Xu YangBowen ChenYanyu WangYunchao WangJunyu LongNan ZhangJingnan XueZiyu XunLinzhi ZhangJiamin ChengJin LeiHuishan SunYiran LiJianzhen LinFucun XieDongxu WangJie PanKe HuMei GuanLi HuoJie ShiLingxiang YuLin ZhouJinxue ZhouZhenhui LuXiaobo YangYilei MaoXinting SangYinying LuHaitao Zhao

Published in: Hepatology international (2023)

This real-world study of lenvatinib plus PD-1 inhibitor treatment demonstrated long survival and considerable ORRs and DCRs in uHCC patients in China. The tolerability of combination therapy was acceptable but must be monitored closely.

Keyphrases

prognostic factors
end stage renal disease
combination therapy
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
clinical trial
squamous cell carcinoma
radiation therapy
open label
patient reported
smoking cessation